Stock Research Report: NTPC, Lupin, NCC and Ahluwalia Contracts
Quick answer: This August 2026 snapshot compares NTPC (P/E about 12x), Lupin (about 17-19x), NCC (about 13x) and Ahluwalia Contracts (about 18x), each trading below its sector peers after Q1 FY27 results. The ratings quoted are third-party brokerage views, not Money n Wealth recommendations; Money n Wealth is not a SEBI-registered research analyst.
Key takeaways
Quick answer: This August 2026 snapshot compares NTPC (P/E about 12x), Lupin (about 17-19x), NCC (about 13x) and Ahluwalia Contracts (about 18x), each trading below its sector peers after Q1 FY27 results. The ratings quoted are third-party brokerage views, not Money n Wealth recommendations; Money n Wealth is not a SEBI-registered research analyst. Key takeaways NTPC: Q1 FY27 PAT up about 13% to roughly ₹6,900 crore; P/E about 12x against Power Grid's ~16x and NHPC's ~20x. Lupin: Q1 FY27 revenue up 33% to ₹8,217 crore; management flagged rising US generic competition. NCC: record order book of ₹81,214 crore (+16% YoY), but PAT lagged on higher finance costs. Ahluwalia Contracts: EBITDA margin fell from 8.6% to 4.3% and PAT 78% in Q1 FY27; order book about ₹20,664 crore. Not a recommendation: brokerage ratings quoted are third-party opinions with dates; Money n Wealth gives no buy or sell calls. Four very different businesses — a power major, a pharma exporter and two construction contractors — share one theme right now: each trades at a discount to its immediate sector peers. Here's a sourced snapshot of NTPC, Lupin, NCC and Ahluwalia Contracts. Snapshot (approximate prices, August 2026) Stock CMP P/E Context NTPC ~₹341 ~12x Steady PSU power major, below sector peers Lupin ~₹2,180–2,220 ~17–19x Pharma growth at a discount to the sector NCC ~₹149 ~13x Record order book, construction-sector discount Ahluwalia Contracts ~₹650 ~18x Debt-free, but margins hit hard in Q1 NTPC (NSE: NTPC) — India's power major, trading at a PSU discount Market cap ~₹3.3 lakh crore, P/E ~12x versus peers Power Grid (~16x) and NHPC (~20x). Q1 FY27 consolidated PAT rose about 13% YoY to roughly ₹6,900 crore on 7.8% revenue growth. Group capacity has crossed 89 GW with a large renewable and nuclear pipeline, targeting 149 GW by 2032. Key risks: execution and funding on that capex plan, and discom payment cycles. Brokerages are mixed post-Q4: Motilal Oswal Neutral (TP ₹393), Axis Direct Buy (TP ₹430), ICICI Securities Buy (TP ₹481) — no post-Q1 FY27 target was independently verified. Lupin (NSE: LUPIN) — pharma growth at a sector discount P/E ~17–19x against the Nifty Pharma index's ~40x. Q1 FY27 revenue rose 33% YoY to ₹8,217 crore, its 16th straight quarter of growth, led by the US (42% of sales) and India (29%). PAT grew a slower 16% as management flagged rising US generic competition (tolvaptan, mirabegron) heading into FY27. Brokerage views vary: Motilal Oswal Neutral (TP ₹2,500), JM Financial cut its target to ₹1,806; a broader Trendlyne consensus (pre-Q1) averaged a Hold near ₹2,452. NCC Limited (NSE: NCC) — record order book, construction-sector discount P/E ~13x versus construction peers averaging well above 20x. Q1 FY27 revenue hit a record ₹5,800-plus crore (+12% YoY) on a consolidated order book of ₹81,214 crore (+16% YoY, about 3.5x book-to-bill). PAT growth lagged revenue on rising finance costs and leverage; management's FY27 guidance was conservative, citing uncertainty on client fund approvals. Brokerage targets, mostly pre-dating Q1 FY27, range from ICICI Direct's Buy at ₹180 to IDBI Capital's Buy at ₹225. Ahluwalia Contracts (NSE: AHLUCONT) — debt-free, but margins under pressure Down sharply from over ₹830 a month ago after a weak Q1 FY27: EBITDA margin fell from 8.6% to 4.3% and PAT dropped 78% YoY, hurt by a billing reduction on one hospital project and NCR wage inflation. Order book remains strong at about ₹20,664 crore (+40% YoY, roughly 4.5x revenue) and the balance sheet is virtually debt-free. Post-results, Prabhudas Lilladher maintains Buy (TP ₹930, cut from ₹1,045) while ICICI Securities is at Hold (TP ₹780). All four operate on different cycles, but the discount each carries traces to a specific, identifiable reason — PSU status, US pricing pressure, execution risk, or a one-quarter margin miss — rather than a blanket market mispricing. None of the brokerage targets above are Money n Wealth's own view; they are third-party opinions, cited with source and approximate date, and should be read alongside each company's own filings. Comparison table of NTPC, Lupin, NCC and Ahluwalia Contracts: P/E, peer valuation, Q1 FY27 results and key risks, as of August 2026; not a stock recommendation Valuation, Q1 FY27 results and key risks at a glance (August 2026) How to Read This Report This page is a factual summary of public information: company results for the April-June 2026 quarter (Q1 FY27), approximate market prices and valuations around 26 August 2026, and ratings published by SEBI-registered brokerages. It is not research issued by Money n Wealth. No Money n Wealth rating: Money n Wealth is not a SEBI-registered research analyst or investment adviser and gives no buy, sell or hold call on these or any other stocks. Attributed views only: every rating and target price above belongs to the named brokerage and may pre-date the latest results. Dated numbers: prices and P/E multiples move daily; check current exchange data and the companies' own filings before drawing conclusions. If you act on stock research, check that it comes from a SEBI-registered research analyst; our guide to what SEBI-registered equity research involves (/insights/what-sebi-registered-equity-research-actually-involves) explains how. Related reading on Money n Wealth What SEBI-registered equity research actually involves (/insights/what-sebi-registered-equity-research-actually-involves) How direct equity is taxed in India in 2026 (/insights/direct-equity-investing-india-taxation-guide) Market wrap: Sensex and Nifty on 13 August 2026 (/insights/market-wrap-13-august-2026-sensex-nifty) All direct equity articles (/insights/category/direct-equity) FAQs Does trading below peers mean these stocks are undervalued? Not automatically — a valuation discount often reflects a specific, identifiable risk, not a market mispricing. It's a starting point for research, not a conclusion. Should I buy these stocks based on this report? No — this is a factual snapshot of public information, not a recommendation. Please do your own due diligence or speak with a qualified adviser before acting. Is Money n Wealth a SEBI-registered research analyst? No. Money n Wealth (Predics Fintech Services Pvt Ltd) is an AMFI-registered mutual fund distributor and APMI-registered PMS distributor, not a SEBI-registered research analyst or investment adviser. This page does not carry a Money n Wealth rating or target on any stock; the views quoted belong to the named brokerages. Where do the brokerage ratings and target prices in this report come from? They are published views of SEBI-registered brokerages such as Motilal Oswal, Axis Direct, ICICI Securities, JM Financial, ICICI Direct, IDBI Capital and Prabhudas Lilladher, as reported around the time of writing. Several pre-date the Q1 FY27 results, so check each brokerage's latest report before relying on them. How current are the prices and valuations in this report? Prices and P/E multiples are approximate and reflect the period around publication on 26 August 2026, after Q1 FY27 (April-June 2026) results. Share prices, valuations and brokerage views change quickly, so treat these numbers as a dated snapshot and check current exchange data and company filings. If you're weighing direct stock ideas like these against fund-based options, see our mutual fund planning guide (/insights/mutual-fund-planning-guide-india) and SIP planning guide (/insights/sip-planning-guide-india) . This week also saw the Hindustan Copper OFS (/insights/hindustan-copper-ofs-2026-how-to-apply) and five new IPOs — including Symbiotec Pharmalab (/insights/symbiotec-pharmalab-ipo-review) in the same pharma space as Lupin, and Lumino Industries (/insights/lumino-industries-ipo-review) in the power-equipment space alongside NTPC. Disclaimer: This report is for informational and educational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. Brokerage ratings and target prices cited are third-party opinions, not Money n Wealth's own view, and may be dated. Past performance and analyst estimates do not guarantee future returns. Please consult your financial adviser and read company filings before investing. Investments are subject to market risks. Money n Wealth (Predics Fintech Services Pvt Ltd) is an AMFI-registered Mutual Fund Distributor (ARN-121995) and APMI-registered PMS Distributor (APRN07444); it is not a SEBI-registered investment adviser and may earn distribution commission on investments made through it.
Frequently Asked Questions
Does trading below peers mean these stocks are undervalued?
Not automatically — a valuation discount often reflects a specific, identifiable risk, not a market mispricing. It's a starting point for research, not a conclusion.
Should I buy these stocks based on this report?
No — this is a factual snapshot of public information, not a recommendation. Please do your own due diligence or speak with a qualified adviser before acting.
Is Money n Wealth a SEBI-registered research analyst?
No. Money n Wealth (Predics Fintech Services Pvt Ltd) is an AMFI-registered mutual fund distributor and APMI-registered PMS distributor, not a SEBI-registered research analyst or investment adviser. This page does not carry a Money n Wealth rating or target on any stock; the views quoted belong to the named brokerages.
Where do the brokerage ratings and target prices in this report come from?
They are published views of SEBI-registered brokerages such as Motilal Oswal, Axis Direct, ICICI Securities, JM Financial, ICICI Direct, IDBI Capital and Prabhudas Lilladher, as reported around the time of writing. Several pre-date the Q1 FY27 results, so check each brokerage's latest report before relying on them.
How current are the prices and valuations in this report?
Prices and P/E multiples are approximate and reflect the period around publication on 26 August 2026, after Q1 FY27 (April-June 2026) results. Share prices, valuations and brokerage views change quickly, so treat these numbers as a dated snapshot and check current exchange data and company filings.
